Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2025)

Historic Assets Average for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $343.1 million.

  • ARS Pharmaceuticals' Assets Average rose 5612.52% to $343.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.1 million, marking a year-over-year increase of 5612.52%. This contributed to the annual value of $292.2 million for FY2024, which is 1354.74% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Assets Average is $343.1 million, which was up 5612.52% from $320.4 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Assets Average high stood at $374.6 million for Q2 2021, and its period low was $187.0 million during Q1 2022.
  • In the last 5 years, ARS Pharmaceuticals' Assets Average had a median value of $276.3 million in 2022 and averaged $277.1 million.
  • Its Assets Average has fluctuated over the past 5 years, first tumbled by 2146.85% in 2022, then skyrocketed by 5612.52% in 2025.
  • ARS Pharmaceuticals' Assets Average (Quarter) stood at $207.0 million in 2021, then soared by 33.45% to $276.2 million in 2022, then fell by 12.81% to $240.9 million in 2023, then increased by 18.06% to $284.4 million in 2024, then rose by 20.66% to $343.1 million in 2025.
  • Its last three reported values are $343.1 million in Q3 2025, $320.4 million for Q2 2025, and $339.2 million during Q1 2025.